MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, found.
|Articles|December 29, 2017
Supplements and Featured Publications
- Pseudobulbar Affect: Considerations for Managed Care Professionals
- Volume 23
- Issue 18
Posttest
Advertisement
Release date:
November 20, 2017
Expiration date:
November 20, 2018
Physician Credit
Instructions for Receiving Continuing Pharmacy Education (CPE) Credit: Testing and Grading Information
This lesson is free online. Receive instant grading and request your CE credit at www.PharmacyTimes.org.
Testing and Grading Directions
- Each participant evaluating the activity and achieving a passing grade of 70% or higher on the online posttest is eligible to receive CE credit.
- Participants receiving a failing grade on the exam will be notified and permitted to take 1 reexamination at no cost.
- To receive your credit online, go to www.PharmacyTimes.org and complete the online posttest (achieving a passing grade of 70% or better) and the online activity evaluation form before the expiration date. Your CE credit will be automatically uploaded to CPE Monitor™. Please ensure your Pharmacy Times® account is updated with your NABP e-profile ID number and your date of birth (MMDD format). Participation data will not be uploaded into CPE Monitor™ if you do not have your NABP e-profile ID number and date of birth entered into your profile on www.PharmacyTimes.org.
Articles in this issue
almost 9 years ago
Pharmacotherapeutic Management of Pseudobulbar Affectalmost 9 years ago
Participating FacultyAdvertisement
Related to this article
This moves the noncovalent BTK inhibitor into the first-line setting for certain adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.
This week in health equity and access: PMOS diagnosis, HIV lung cancer screening, transplant access, atopic dermatitis care, and value-based oncology.
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Patch testing in Malaysia finds contact dermatitis drivers in chronic hand eczema—nickel and fragrance allergy lead, while cosmetics raise polysensitization risk.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
The article explores the use of dose-intensive IV iron replacement to achieve long-term hemoglobin stability in patients with moderate to severe HHT-related bleeding. The approach recognizes what the author calls "the relentless and recurrent nature of HHT-associated bleeding," and may help patients achieve better quality of life.
Advertisement
Advertisement
Trending on AJMC
1
Preparing Practices for the Next Era of Hepatitis B Care
2
Lung Cancer Screening Lags for People With HIV as Eligibility Triples
3
VYD2311 Shows Superior Safety vs mRNA COVID-19 Vaccine
4
CMS Finalizes Mandatory GLOBE Model to Test Lower Part B Drug Costs
5